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To the Editor: Van Wyck et al.1 administered 1 g intravenous
(i.v.) iron over the first 2 weeks, whereas oral iron was given
over 8 weeks. As the rates of administration of iron were
different, the appropriate comparison should be the propor-
tion of patients achieving the primary end point at the end of
10–12 weeks and make the results more clinically relevant. In
the analysis presented, it is assumed that patients who
achieved 1 g/dl increase in hemoglobin at 2 weeks would also
have the same response at 56 days. In the interest of
intention-to-treat, the authors should also present the data
for all patients randomized even when erythropoietin dose
was not stable at baseline. The authors should be cautious in
concluding that i.v. iron is safe in the long term. Progression
of chronic kidney disease takes years and it would appear
naive to declare safety of i.v. iron by reporting two estimated
glomerular filtration rates over a course of 56 days! Notably,
the improvement in hemoglobin with i.v. iron was only 0.3 g/
dl more in the i.v. iron group, and 2/30 patients who received
the high dose of 500 mg iron sucrose experienced severe
hypotension sufficient to visit the emergency room. Thus,
caution is warranted, when using high-dose i.v. iron. The
authors measured C-reactive protein, yet do not report the
data. Change in proteinuria was not reported and the
multivariate logistic model for odds of hemoglobin response
was also not presented as stated in the methods. These
additional data would help interpret the results of this trial
better.
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Dr Agarwal1 raises a number of important questions. The
answer to the title question would seem to be yes, i.v. iron
is superior to oral iron. Moreover, the degree of difference
is clinically significant: in chronic kidney disease patients
with anemia (hemoglobin (Hb) o11 g/dl) without ery-
thropoiesis-stimulating agents (ESA) or without an in-
crease in ESA dose, i.v. iron administration will raise the
Hb higher, stimulate a Hb increase 41.0 g/dl more often,
achieve or exceed the target Hb threshold of X11.0 g/dl
more consistently, and replete iron stores more reliably
than oral iron therapy. The answer to whether we should
have included patients with ESA dose increases in the
analysis of efficacy is no. Increasing ESA doses, like
starting ESA anew, administering additional i.v. iron off
protocol, or transfusing the patient, introduces a co-
intervention. The penalty for including co-interventions is
the inability to isolate iron treatment effects. As we
discussed, previous randomized controlled trials that failed
to preclude co-interventions failed to show between-group
differences in patients assigned to i.v. iron or oral iron
treatment.2,3
Was the duration of the trial sufficient to show efficacy?
We demonstrated that the peak Hb response in both
treatment groups occurred before 42 days, well before
completion of the 56-day observation period. Among
patients assigned to oral iron, peak increase in Hb was
lower than in i.v.-treated patients, as we showed, but time
to peak increase did not differ between groups (Cox
proportional hazards model: 36.1 vs 39.9 days, oral vs i.v.;
P¼ 0.3481). Logistic regression analysis yielded only
baseline ferritin o100 ng/ml as a significant covariate in
increasing the odds of a positive Hb response, a result we
explored in more detail in the analyses we presented in
Table 2.
Was the duration of the trial sufficient to conclude that
i.v. iron, compared to oral iron, is safe in patients with
chronic kidney disease? Three randomized controlled
trials, including ours, have examined the effect of i.v. iron
administration compared to oral iron therapy on renal
function in chronic kidney disease patients. In the first,
patients given i.v. iron sucrose 300 mg monthly up to 6
months showed a rate of decline of renal function no
different from that seen in patients given oral iron.2 In the
second, patients assigned to oral iron therapy showed a
significant decline in ClCr, whereas their counterparts
given i.v. iron dextran 100 mg twice monthly up to 3
months showed no decline.4 Our results in patients who
received five 200 mg doses or two 500 mg doses of iron
sucrose showed a slower rate of decline of glomerular
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